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Abstract 
 
Alzheimer’s disease (AD) is an age-specific neurodegenerative disease that 
compromises cognitive functioning and impacts the quality of life of an individual. 
Pathologically, AD is characterised by abnormal accumulation of beta-amyloid (Ab) 
and hyperphosphorylated tau protein. Despite research advances over the last few 
decades, there is currently still no cure for AD. Although, medications are available to 
control some behavioural symptoms and slow the disease’s progression, most 
prescribed medications are based on cholinesterase inhibitors. Over the last decade, 
there has been increased attention towards novel drugs, targeting alternative 
neurotransmitter pathways, particularly those targeting serotonergic (5-HT) system. 
In this review, we focused on 5-HT receptor (5-HTR) mediated signalling and drugs 
that target these receptors. These pathways regulate key proteins and kinases such 
as GSK-3 that are associated with abnormal levels of Ab and tau in AD. We then 
review computational studies related to 5-HT signalling pathways with the potential for 
providing deeper understanding of AD pathologies. In particular, we suggest that 
multiscale and multilevel modelling approaches could potentially provide new insights 
into AD mechanisms, and towards discovering novel 5-HTR based therapeutic 
targets. 
 
Introduction 
 
Dementia is a clinical syndrome caused by a number of progressive illnesses that 
affect cognition, behaviour and the ability to perform daily activities (Weller and 
Budson, 2018). Dementia is one of the main causes of dependence and disability at 
older ages. Alzheimer’s disease (AD) is the most common form of dementia affecting 
approximately 50 million people worldwide (Baldas et al., 2011). It has been estimated 
that by 2050, 115 million people worldwide will be living with AD (Wortmann, 2012). 
Other types of dementia include vascular dementia, frontotemporal dementia, Lewy 
body dementia, Huntington’s disease, and Creutzfeldt-Jakob disease, and co-
morbidity of AD with some of these are not uncommon (Gale et al., 2018). An 
intermediate stage between healthy and AD is labelled mild cognitive impairment 
(MCI) (Gale et al., 2018). However, MCI is a loosely defined and heterogenous group, 
consisting of non-neurodegenerative or non-AD converters and people with other 
illnesses e.g. psychiatric illness (Gale et al., 2018). 
 
To a large extent, AD can be categorized as familial AD (family history of the disease) 
or sporadic (late-onset) AD, with the latter overwhelmingly the most common type 
(Dorszewska et al., 2016). Various genes are currently thought to be associated with 
these different AD types. Mutations in amyloid precursor protein (APP), presenilin-1 
(PSEN1) and presenilin-2 (PSEN2) are associated with familial AD while 
apolipoprotein E (ApoE) gene has been linked to the sporadic type (Gale et al., 2018). 
More generally, AD neuropathology has been characterised by the accumulation of β-
amyloid (Aβ) protein due to the aberrant processing of APP, neurofibrillary tangles 
(composing of hyperphosphorylated tau protein), oxidative stress, excitotoxicity, 
neuroinflammation, and impairment in neurotransmitter systems (Butzlaff and 
Ponimaskin, 2016; Francis et al., 1999; Haruhiko et al., 2000; Heneka et al., 2015; 
Hynd et al., 2004; Markesbery, 1997; Rajmohan and Reddy, 2017).  
 
Within the brain, acetylcholine (ACh) is an important neurotransmitter and 
neuromodulator implicated in cognitive functions such as learning and memory, and 
abnormalities (e.g., reduction in presynaptic ACh receptors, diminished choline 
acetyltransferase activity) in cholinergic neurons (which produce ACh) are found in the 
brains of AD patients (Francis et al., 1999). One approach to reducing the rate of 
cognitive decline in AD is to inhibit the breakdown of ACh into inactive metabolites by 
blocking the enzyme acetylcholinesterase responsible for the process. For instance, 
donepezil (Aricept) is a second-generation cholinesterase inhibitor (AChEI) and is the 
most widely prescribed drug for the treatment of AD. A Cochrane review estimated a 
1.37 (95% CI: (1.13,1.61)) Mini Mental State Examination (MMSE) score improvement 
at six months after AChEI initiation (Birks and Harvey, 2018). However, it should be 
emphasised that these drug treatments do not cure AD, but rather delay the rate of 
cognitive decline associated with AD (Douchamps and Mathis, 2017). Hence, 
identifying novel therapeutics, especially repurposed drugs, has become a priority 
research area in both academia and industry.  
 
AD has also been reported to be linked to changes in non-cholinergic 
neuromodulators, especially the monoaminergic systems (Morgese and Trabace, 
2019). In particular, reduced serotonin (5-HT) levels in the neocortex and altered 
serotonin receptor (5-HTR) density are reported with severe cognitive decline in AD 
patients (Lai et al., 2005, 2002). Also, reduced 5-HT transporter (5-HTT) levels are 
reported in cortical, limbic, sensory, motor, striatal and thalamic brain regions in MCI 
as compared to healthy controls. Such reduction in 5-HTT levels is also found in the 
AD patient’s temporal cortex (Smith et al., 2017; Tsang et al., 2003). These 
pathological conditions are possible grounds of underlying depressive symptoms, 
commonly seen in AD patients, and can potentially play an important role in the 
pathophysiology of AD (Smith et al., 2017).  
 
Depression seems to be common in 20-30% of patients with AD (Tsuno and Homma, 
2009). In fact, AD and depression share a close relationship: depression can lead to 
higher risk of AD but AD may also contribute to depression (Galts et al., 2019; Ownby 
et al., 2006). For instance, progression of AD is often associated with stress due to the 
catastrophic decline in motor and cognitive functions which can trigger the neural 
circuits involved in mediating stress response (Justice, 2018). Such chronic exposure 
of stress disrupts the cascades of stress hormones (e.g., cortisol) and affects the brain 
areas involved in monoaminergic transmission (e.g., dorsal raphe), decision making 
(e.g., prefrontal cortex), anxiety, and hence, increase the risk of developing depression 
(Arnsten, 2009; Bocchio et al., 2016; Hannibal and Bishop, 2014; Sengupta et al., 
2017; Tafet et al., 2001).  
 
Further, administration of antidepressants such as selective serotonin reuptake 
inhibitors (SSRIs) is often prolonged in chronically depressed patients, and long-term 
usage of SSRIs is associated with many side effects including cognitive impairments 
(e.g., memory deficits) (Prado et al., 2018; Sayyah et al., 2016). This gives rise to the 
possibility that extended use of SSRIs can increase the risk of developing dementia 
or AD.  Practically, it is very challenging to establish a link between depressed 
individuals and late-life AD, as there are many constraints for long-term studies. Only 
a handful of studies attempted to establish such a link. For instance, a meta-study by 
Wang and colleagues suggests that antidepressant usage is substantially linked with 
a greater risk of developing dementia (Wang et al., 2018). These findings are not 
consistent with a study by Kessings and colleagues that suggests sustaining long-term 
treatment of SSRIs does not affect the risk of having dementia (Kessing et al., 2011). 
In contrast, a study by Xie and colleagues shows a pacified effect of SSRIs (e.g., 
fluoxetine) on cognitive performance in AD (Xie et al., 2019). Another study shows 
SSRIs to be beneficial in delaying the onset of AD on patients with a history of 
depression, a known risk factor for AD (Elsworthy and Aldred, 2019). Thus, these 
mixed results suggest that further studies are needed.  
 
Amidst these mixed behavioural results, at the biological level, the effects are clearer. 
For example, the administration of SSRIs in AD in human studies (Lyketsos et al., 
2003) and preclinical studies (animal models) have demonstrated a commendable 
influence of SSRIs on pathological markers of AD including Ab accumulation, tau 
deposits, and neurogenesis (Kim et al., 2013; Qiao et al., 2016; Sheline et al., 2014; 
Wang et al., 2014, 2016). As the administration of SSRIs, including in AD, can increase 
the level of 5-HT, which leads to the activation of several 5-HTRs (Tajeddinn et al., 
2016; Tohgi et al., 1995), we shall next discuss in more detail the various effects of 5-
HTR targeted drugs, with focus on 5-HT heteroreceptors, postsynaptic sites and AD.  
 
Serotonin receptor targeted drugs 
 
5-HT receptors (5-HTR) are abundant throughout the brain with 14 known receptor 
subtypes and categorised into 7 subfamilies, 5-HT1-7 (Stiedl et al., 2015). Apart from 
5-HT3R, all other 5-HT receptors act via G-protein coupled receptors (GPCR) (Hannon 
and Hoyer, 2002; Masson et al., 2012). 5-HT3, the only 5-HT based ligand-gated ion 
channel, acts via changes in cation currents (e.g., Na+, Ca2+) (Masson et al., 2012). 
Numerous studies have associated 5-HT3 mediated drugs with the accumulation of 
specific proteins found in AD (Fakhfouri et al., 2019; Huang et al., 2020; Skovgård et 
al., 2018). For example, in a rat model of AD, a study showed a protective response 
of a drug, tropisetron, a 5-HT3 receptor antagonist, on Ab-induced  neurotoxicity on 
neurons in the hippocampus, a brain region associated with cognitive functions such 
as memory and spatial navigation (Rahimian et al., 2013). The hippocampus is known 
to be one of the regions of deterioration in early-stage AD (Gale et al., 2018). A follow-
up study indicated that tropisetron protects rat pheochromocytoma cells (PC12) from 
oxidative-induced neurotoxicity via a7 nicotinic acetylcholine receptor (a7nAChR, 
which respond to ACh) and 5-HT3R antagonist (Khalifeh et al., 2015). However, when 
a 5-HT3 selective antagonist (ondansetron) is combined with acetylcholinesterase 
inhibitors (e.g., donepezil) in rats, they together potentiate and prolong the theta and 
gamma-band neural oscillations induced by donepezil alone. Such changes in 
hippocampal network oscillations and theta-gamma coupling are reported in a mouse 
model of AD, before the excessive production of Aβ (Goutagny et al., 2013; Skovgård 
et al., 2018).  
 
In contrast to 5-HT3R, the rest of the 5-HTR subtypes are associated with G protein-
coupled receptors (GPCRs). In particular, the G-proteins for 5-HT1R and 5-HT5R act 
as members of the Gi/o family of receptors (Masson et al., 2012) (Fig. 1). Activation of 
these receptors regulates various signalling pathways including protein kinase A 
(PKA) pathways (Fig. 1) (Masson et al., 2012). 5-HT1R are expressed in large numbers 
in the hippocampus and are known to play a significant role in the regulation of memory 
processes (Ögren et al., 2008). Studies have also linked the level of 5-HT1AR with 
agitative/aggressive behaviour (symptoms of AD), and the various stages of AD (Lai 
et al., 2003). Specifically, for the latter, a higher density of 5-HT1AR was reported 
during the early stage of AD as compared to healthy controls (Truchot et al., 2008, 
2007), whereas lower levels were detected during the advanced stage of AD (Becker 
et al., 2014; Kepe et al., 2006; Lanctôt et al., 2007; Vidal et al., 2016). In contrast, a 
post-mortem study indicated higher neocortical 5-HT1A density and relatively lower 5-
HT levels in the brain tissue of AD patients as compared to healthy controls (Lai et al., 
2002). There is also evidence that the drug Lecozotan, a 5-HT1AR antagonist, can be 
used to improve cognitive dysfunction associated with AD, as the drug potentially 
interacts and enhance the signalling pathways of other neurotransmitters (e.g. 
cholinergic, glutamatergic) systems (Schechter et al., 2005). 
 
Unlike 5-HT1R, 5-HT2R are coupled to Gq proteins and activate various signalling 
pathways including PKC and calcium/calmodulin-dependent kinase II (CaMKII), with 
the latter acting as a key protein kinase in neural plasticity and memory (Fig. 1). 
Several studies have linked the density of 5-HT2R with Ab levels and cognitive 
impairment (Hasselbalch et al., 2008; Lai et al., 2005; Maroteaux et al., 2017; Nitsch 
et al., 1996; Štrac et al., 2016). In rats, intra-hippocampal injection of Ab1-42 reduces 
5-HT2ARs and impairs memory (Holm et al., 2010). Not surprisingly, 5-HT2AR 
expression levels were also reduced at the projection sites such as the medial 
prefrontal cortex (Christensen et al., 2008; Holm et al., 2010; Lorke et al., 2006). 
Additionally, the 5-HT2R gene (T102C) is also reported to be involved in hallucination, 
psychosis and aberrant motor behaviour associated with AD (Tang et al., 2017). 
Recently, a study by Afshar and colleagues reported that 5-HT2AR antagonist (NAD-
299) individually, and in combination with 5-HT1AR antagonist (TCB-2), significantly 
reduces oxidative stress and neuronal loss in hippocampal neurons in a rat model of 
AD (Afshar et al., 2019). Moreover, 5-HT seems to directly regulate Ab via amyloid 
precursor proteins (APPs) via 5-HT2AR and 5-HT2CR with different signalling pathways 
as they lead to the formation of APPs and ultimately the accumulation of Ab (Fig. 1); 
this effect is blocked by 5-HT antagonists (ketanserin, mianserin, and ritanserin) 
(Nitsch et al., 1996). 
 
The other classes of 5-HTRs, 5-HT4R, 5-HT6R, and 5-HT7R are coupled with Gs 
proteins and activate various signalling pathways including protein kinase A (PKA) and 
extracellular signal-regulated kinase (ERK) (Fig. 1). Compared to other 5-HT 
receptors, 5-HT4R targeted drugs have lately attracted considerable research interest, 
as many recent research studies have investigated its therapeutic potential in the 
treatment of AD (Bockaert et al., 2008). 5-HT4R has been associated with learning and 
memory (Bockaert et al., 2008; Hagena and Manahan-Vaughan, 2017). 5-HT4R 
expression has been found to be reduced in AD patients, while the activation of these 
receptors inhibits the (e.g., AC-cAMP-PKA) biochemical cascades that lead to AD  
(Fig. 1) (Hagena and Manahan-Vaughan, 2017; Reynolds et al., 1995).  
 
Additionally, 5-HT4R agonists have been found to improve cognitive deficits in AD 
(e.g., Claeysen, Bockaert and Giannoni, 2015). For instance, Madsen and colleagues 
have reported that cerebral 5-HT4R binding is directly linked to abnormal accumulation 
of Aβ in AD patients (Madsen et al., 2011). Several other studies have also indicated 
that 5-HT4R agonists (e.g., RS6733, a partial agonist) inhibit the production of Ab in 
the entorhinal cortex, a region of deterioration in early-stage AD (Gale et al., 2018), by 
promoting the production of the neurotropic soluble APP alpha (sAPPa) and helps in 
improving cognitive abilities (learning and memory) in animal models of AD (Baranger 
et al., 2017; Yahiaoui et al., 2016). Further, RS6733 is also used with nicotinic receptor 
allosteric modulator/cholinesterase inhibitor galantamine to compensate for the deficit 
associated with short- and long-term memory (Freret et al., 2017). Interestingly, 
RS67333 also acts as an acetylcholinesterase (AChE) inhibitor and helps in reviving 
the cholinergic functions which are typically altered in AD (Lecoutey et al., 2014). 
Moreover, chronic administration of this drug decreases the levels of Ab in the 
hippocampus in 5XFAD mouse model (expressing human APP and PSEN1 
transgenes) of AD (Giannoni et al., 2013). However, when another 5-HT4R agonist, 
SSP-002392, is applied to cultured human neuroblastoma cells, it increases sAPPa 
and cyclic adenosine monophosphate (cAMP) levels at a lower concentration than 
other well-known agonists (e.g., prucalopride), and suggesting the neuroprotective 
effect is mediated by EPAC (an exchange nucleotide protein directly activated by 
cAMP; Fig. 1) signalling (Cochet et al., 2013).  
 
Apart from 5-HT4R, 5-HT6R has also attracted substantial research interest in the last 
few years. For instance, a 5-HT6R antagonist, SB271046 has been found to recover 
memory impairment by reducing the levels of Ab via inhibiting the gamma-secretase 
activity (multi-subunit enzyme that produces Ab) in a mouse model of AD (Yun et al., 
2015). Stimulation of these receptors primarily modulates the extracellular 
concentration of glutamate and GABA in various neural circuits and contributes to the 
release of other neuromodulators (e.g., dopamine, norepinephrine (Ne), ACh) which 
are known to be impaired in AD (Khoury et al., 2018). Similarly, another 5-HT6R 
antagonist, idalopirdine (Lu AE58054), interacts with other neurotransmitter systems 
and increases the extracellular levels of dopamine, noradrenaline, and glutamate in 
the mPFC (de Jong and Mørk, 2017).  Additionally, it has been suggested that these 
5-HT6R antagonists may have synergistic effects when combined with 
acetylcholinesterase inhibitors (e.g., donepezil), but recent phase III trials have 
reported no additional benefit or significant improvements in cognitive functions 
(Andrews et al., 2018).  
 
As with the other 5-HTRs, 5-HT7R is highly expressed in the hippocampus and plays 
an important role in memory formation, neuronal function and neurogenesis (Hashemi-
Firouzi et al., 2017; Meneses, 2014; Shahidi et al., 2019). For example, activation of 
the 5-HT7R via AS19, a selective serotonin agonist, improves synaptic impairment in 
a rat model of AD by decreasing apoptosis (programmed cell death) in the 
hippocampus (Hashemi-Firouzi et al., 2017) and could potentially hinder the 
progression of AD.  
 
Additionally, glycogen synthase kinase (GSK-3) appears to be an important 
component in many 5-HT receptor-mediated signalling pathways (Fig. 1). Overactivity 
of GSK-3 is implicated in both familial and sporadic forms of AD in terms of increased 
levels of plaques and tangles (Polter and Li, 2011). In general, GSK-3 is a ubiquitously 
present kinase that exists is two isoforms (GSK-3α and GSK-3β). Its activation largely 
depends upon the phosphorylation by upstream kinases including 5-HT mediated 
pathways (Fig. 1) (Lauretti et al., 2020; Polter and Li, 2011). It regulates key 
downstream biological pathways that are potentially involved in a range of diseases 
and disorders including cancer, diabetes, bipolar disorder, and neurodegeneration, 
and are often considered as a potential therapeutic target by many drug companies 
(Pandey and DeGrado, 2016; Saraswati et al., 2018). 
 
For animal models of AD, several studies have reported that elevated GSK-3β activity 
is associated with increased levels of Ab and tau hyperphosphorylation (Lauretti et al., 
2020; Llorens-Martín et al., 2014). The functionality of GSK-3β can be regularised by 
phosphorylation/dephosphorylation that occurs at different sites (Lauretti et al., 2020). 
For example, phosphorylation on tyrosine-279/216 activates its activity while 
phosphorylation on serine 21/9 via different kinases (e.g., Akt, PKA) inhibits it (Sayas 
et al., 2006). Generally, GSK-3b activation is associated with generation and 
deposition of Aβ (Fig1). This is a multi-step process and involves modulation of the 
APP cleavage via different pathways (non-amyloidogenic, amyloidogenic) and 
includes synergic action of various enzymes. The non-amyloidogenic pathway of APP 
involves alpha-secretase (ADAM10, ADAM17) and gamma-secretase enzymes, and 
forms a degradable peptide (Lauretti et al., 2020). The amyloidogenic pathway 
includes the sequential action of beta-secretase (BACE-1) and gamma-secretase 
enzymes and constitutes intermediates: fibril and oligomers that eventually converts 
to Aβ (Lauretti et al., 2020; Llorens-Martín et al., 2014). In particular BACE-1 activity 
is elevated in AD patients (Decourt and Sabbagh, 2011). Further, studies have 
reported that inhibition of GSK-3β reduces BACE-1 mediated APP cleavage and 
ultimately reduces the Aβ levels (Lauretti et al., 2020; Ly et al., 2013). GSK-3 inhibitor 
(SAR502250) also provide neuroprotective effect in the animal model of AD (Griebel 
et al., 2019). Additionally, GSK-3β plays a key role in tau phosphorylation. GSK-3β 
phosphorylates at different sites including Thr231 and leads to the separation of 
microtubules that fosters the generation of tau oligomers and neurofibrillary tangles 
(NFTs) (Lauretti et al., 2020). Given the above results, GSK-3 inhibitors (e.g., 
Tideglusib) are currently undergoing phase II clinical trials (Griebel et al., 2019). 
 
There is also evidence that 5-HT based drugs (e.g. SSRIs) interact with GSK 
pathways, and are effective in lowering some of the proteins that are impaired during 
AD. Specifically, the SSRI escitalopram was found to reduce Ab1-42 induced 
hyperphosphorylation of tau via the 5-HT1AR mediated Akt/GSK-3b pathway in the 
hippocampal neurons (Wang et al., 2016) (Fig. 1) and this could be a key pathway for 
the potential treatment of AD, especially in its early stage. Furthermore, SSRI can also 
modulate GSK-3b signalling to regulate the neurogenesis in hippocampus neurons via 
activation of 5-HT1AR (Fig.1 ) (Hui et al., 2015). Overall, these studies suggest that 
SSRIs and 5-HTR based drugs, and their combinations with other targeted 
neuromodulator (e.g. ACh) receptors, have the potential to perturb downward 
signalling pathways involve in the regulation of Ab and tau. Currently, novel drug 
therapeutics for AD targeting the 5-HT system is the subject of intense research given 
that these drugs are already available and currently undergoing Phase II clinical trials 
(Šimić et al., 2017). 
 
However, the system can be rather complex. For instance, it is known that any 
postsynaptic neuron can manifest a combination of two to three 5-HT receptor 
subtypes (Mengod et al., 2010). Thus, a pressing issue for the research community is 
to understand whether 5-HT induced signalling pathways crosstalk with other 
pathways which are impaired in AD. Given that 5-HT receptor subtypes can also 
respond with different affinities (Mengod et al., 2010), drug effects can lead to variable 
activation of intracellular signalling cascades. The complexity is compounded by the 
involvement of a multitude of proteins, enzymes, transporters, related genes, neuronal 
and synaptic properties, and ultimately cognition and behaviour – a multiscale and 
multilevel problem. Thus, the systems’ complexity has hindered a deeper 
understanding of the underlying pathophysiological mechanisms that give rise to the 
abnormal accumulation of Aβ and tau and cognitive decline in AD has yet to be 
achieved.  
 
Computational modelling offers a platform to bridge such a gap and guide drug design 
and development, and treatment (Roy, 2018). One way this can be achieved is through 
the integration of data or information across several experiments and the development 
of biologically based computational models. Indeed, such models have the potential 
to allow systematic exploration across multiple scales of description, beyond current 
experimental capabilities (Wong-Lin et al., 2017). This shall be our next point of 
discussion.  
 
Figure 1. Schematic diagram of 5-HTR mediated signalling pathways: Activation of 5-
HT1AR initiates several pathways including Gai/o-adenylyl cyclase-cAMP-EPAC/PKA 
and Ras, Raf-ERK signalling pathways. When cAMP binds to the subunits of PKA, 
they phosphorylate downstream proteins to regulate key cellular processes. As a 
result, it increases the gene transcription involved in the development of long-term 
memory which is regulated by CREB. Furthermore, it alters the NMDA, AMPA and 
GABA receptor-mediated currents and also plays an active part in modulation of 
voltage-gated Na+, K+ and Ca+2 ion channels. Additionally, 5-HT1R activates Akt via 
PI-3K-PDK pathways. It is a key protein kinase and also regulates phosphor-Ser9-
GSK3b. Similarly, activation of 5-HT2R initiates PLC-DAG-PDK-PKC/IP3-ERCa+2-
PKC pathways. Importantly, the activated form of PKC also regulates phosphor-Ser9-
GSK3b. Also, 5-HT2R affects b-Arrestin-Akt-PP2A signalling pathway. 5-HT: 5-
hydroxytryptamine; SERT: serotonin reuptake transporter; Gαi/o, Gαs, Gαq: isoforms of 
the α subunits of G protein-coupled receptors (GPCR); AC: adenylyl cyclase; cAMP: 
cyclic adenosine monophosphate; EPAC: exchange proteins activated by cAMP; PKA: 
protein kinase A; CREB: cAMP response element-binding protein; Raf: rapidly 
accelerated fibrosarcoma kinase; ERK: extracellular signal regulated kinase; PI-3K: 
phosphoinositide 3-kinases; PDK1: phosphoinositide-dependent kinase1; Akt (a): 
protein kinase B (active); b-Arr: b-arrestin; Akt (in): Protein Kinase B (inactive); PP2A: 
protein phosphatase 2; PLC: phospholipase C; DAG: diacylglycerol; PDK1: 
phosphoinositide-dependent protein kinase-1; IP3: inositol 1,4,5-trisphosphate; PIP2: 
phospholipid phosphatidylinositol 4,5-bisphosphate; ER: endoplasmic reticulum; PKC: 
protein kinase C; GSK-3: glycogen synthase kinase-3, there are two isoforms GSK-
3a, GSK-3b; tau: tau protein; Ab: beta amyloid; P: Phosphorylated. Note: Signalling 
pathway specific to 5-HT metabotropic receptors are shown; for detailed signalling 
networks, see Masson et al. (2012) and Wong-Lin et al. (2017), and for their 
association with GSK, see Polter and Li (2011).  
 
 
Towards multiscale computational modelling of serotonergic 
system 
 
Computational modelling or in silico investigation in preclinical and clinical research is 
an important research component towards facilitating understanding of brain functions 
and diseases such as AD, and for drug discovery and development (Cutsuridis and 
Moustafa, 2017a, 2016, 2017b; Geerts et al., 2017b; Roy, 2018). For years, 
mechanistic models have been developed to provide insights into the mechanism 
underlying the disease, to explore novel drug targets, and to gain a deeper 
understanding of drug actions (De Witte et al., 2016; Meier-Schellersheim et al., 2019; 
Schmidt et al., 2013). In particular, the key attractiveness of a quantitative model, 
captured by mathematical or statistical measures, is to provide a more integrated and 
quantitative understanding of mechanisms and patterns while eliminating ambiguities 
and adding rigour to “mental” models (for intuitive understanding) in 
experimental/clinical neurosciences. As in the field of physical sciences and 
engineering, experimental “what-if” scenarios can be tested in model simulations to 
evaluate hypotheses. Computational models also provide testable model predictions, 
which can guide future experiments (Mazein et al., 2018).  
 
Several computational models of AD pathologies, symptoms and treatments have 
been proposed, and these are covered in recent comprehensive reviews (see e.g. 
Cutsuridis and Moustafa, 2017a, 2017b; Hassan et al., 2018, and references therein). 
Several earlier modelling papers in systems and theoretical biology were emphasised 
more towards understanding the dynamics of Ab accumulation and its interactions with 
other proteins (Hassan et al. (2018)). Later modelling work encompassed the mapping 
of much larger number of biochemical interactions and other more data-driven, using 
either logic-based (Maude Petri net) models (Anastasio, 2011). For instance, such 
models could link Ab effects on synaptic plasticity (Anastasio, 2014), and the search 
for potential combination of drugs to reduce microglial inflammation (Anastasio, 2015). 
More abstract probabilistic graphical (Bayesian) network models were also applied to 
understand key protein/drug interactions at the systems level (Rembach et al., 2015).  
 
To date, there are only a small number of computational modelling studies on 5-HT 
mediated signalling pathways. Importantly, none of the computational studies are 
focused on understanding the role of 5-HT mediated intracellular signalling pathways 
in AD. Hence, these present opportunities for computational modellers to contribute. 
Thus, we shall henceforth first discuss a set of models on 5-HT mediated pathways, 
before discussing a separate set of models on aggregation of Ab and 
hyperphosphorylated tau and tangles. Then, we argue the potential to integrate these 
two sets of models together.  
 
In a highly detailed computational model of 5-HT receptor-mediated signalling, Chang 
et al. (2009) developed a model of 5-HT1AR and 5-HT2AR activated ERK(1/2) pathways 
using Michaelis–Menten formalism and the law of mass action. In the model, 5-HT1AR 
stimulated phosphoinositide 3-kinases (PI-3K) pathway while 5-HT2AR triggered 
mitogen-activated protein kinase (MAPK) / ERK pathway (also known as the Ras-Raf-
MEK-ERK pathway) (Fig. 1). Their model’s key results, in agreement with 
experimental data, showed the dominance of 5-HT2AR over 5-HT1AR in the MAPK 
signalling pathway, and the deleterious effects of regulator/enzymes affecting basal 
levels of ERK. In another modelling work, Zhang et al. (2012), building on the model 
by Pettigrew et al. (2005) (Pettigrew et al., 2005; Zhang et al., 2012), studied the 
effects of 5-HT on PKA-ERK interactions to enhance long-term facilitation of synapses. 
In a similar vein, Zhou et al. (2014) modelled both PKA and PKC signalling to show 
that PKC was sufficient for short-term facilitation of synapses, and that cooperation 
among the signalling cascades could potentially contribute to the enhancement of 
learning and memory, which had recently been validated experimentally (Liu et al., 
2017; Zhou et al., 2014). These results may have implications in AD, given the latter’s 
deterioration in learning and memory. Importantly, these models also laid the 
foundation for modelling 5-HT signalling pathways through PKA and PKC responses 
(Fig. 1).  
 
As discussed earlier, and illustrated in Fig. 1, 5-HT signalling not only involves ERK 
and PKA pathways but also engages the GSK-3 enzymes via 5-HTRs. Also, GSK-3 
can in turn modulate 5-HT1BR, which exists at presynaptic terminals of 5-HT neurons, 
leading to changes in 5-HT level. GSK-3 is inactivated by serine phospho-ser21/Ser9 
(ps21/9), and the latter bridges between 5-HTRs and GSK-3 (Fig. 1). The intermediate 
transcription factor p53, which regulates the expression of cellular stress response 
genes, can interact with GSK-3 (Jazvinšćak Jembrek et al., 2018). Mild oxidative 
stress injury can lead to p53 ensuring antioxidative activities and promoting cell 
survival. But over antioxidative capacity can lead to cell death by p53 (apoptosis). 
Hence, this results in a possible link between 5-HT, GSK-3 and the fields of 
neuroinflammation and immunology.  
 
Such biochemical reaction process involving GSK-3, p53, tau tangles and Ab 
aggregation was first modelled by Proctor and Gray (2010) using Systems Biology 
Markup Language (SBML) and stochastic simulation, building on their previous model 
of p53 (Proctor and Gray, 2008). Their modelling results accounted for the overactivity 
of GSK-3 and p53 after a stress event, leading to increase in Ab and tau tangles, 
providing a correlation between the latter two, but not causation. Later, Proctor et al. 
(2013) extended the model and showed that immunisation helped to clear plaques, 
but limited influence on soluble Ab, phosphorylated tau and tangles, consistent with 
experimental observation (Proctor et al., 2013). Interestingly, the model results 
suggested interventions to be performed at a very early stage of AD. It should also be 
noted that GSK-3 is also associated with other neurodegeneration related to 
tauopathies, such as Pick's diseases, progressive supranuclear palsy and corticobasal 
degeneration (Ferrer et al., 2002). Hence, it may be worth investigating through 
computational modelling to further understand the 5-HT based drug (e.g., SSRI) 
effects and treatments on these other diseases. 
 
Taken together, despite their small number, the abovementioned mechanistic models 
were used as examples which could potentially be integrated to provide a deeper 
understanding of the effects of 5-HT through GSK-3 to aggregation of plaques and tau 
tangles and subsequent changes in neuronal and synaptic properties, and potential 
novel therapeutics. For instance, 5-HT induced PKA and PKC pathways can modulate 
at least four membrane currents including 5-HT sensitive, voltage-dependent and 
calcium-activated potassium currents and L-type calcium currents (Baxter et al., 
1999). Notably, modulation of voltage-dependent potassium currents by PKC plays a 
significant part in the broadening of spikes (Baxter et al., 1999). In contrast, 
simultaneous modulation of 5-HT sensitive potassium and calcium current increases 
the excitability within cells, potentially due to the indirect crosstalk among PKC and 
PKA pathways. Further, Ab can interact with membrane ion channel currents and can 
affect their overall excitability. For example, computational studies by Zou and 
colleagues showed that Ab blocked A-type currents and increased the excitability of 
pyramidal neurons, and subsequently the excitability of the (hippocampal septal) 
microcircuit (Zou et al., 2012, 2011). This could in turn lead to memory impairment and 
even symptoms of epileptic seizures, a common comorbidity in AD (Zou et al., 2012). 
Complementary to these studies, Abuhassan and colleagues used a large-scale 
model to understand the effects of synaptic loss, due to AD, on global 
oscillatory dynamics (Abuhassan et al., 2014). Thus, there is the potential for 
computational models to bridge from one level of description to another – multiscale 
and multilevel modelling. However, linking from one modelling scale/level to another 
requires its abstraction (Wong-Lin et al., 2017).  
 
In fact, a challenge to mechanistic models lies in how they can be utilised when certain 
components of the network are not parameterised or missing, which can impact on 
model accuracy (Fröhlich et al., 2018). A practical way to estimate the optimal set of 
model parameter values is to fix certain known model parameters and manipulate 
others within a physiologically reasonable range until the model is able to mimic 
experimentally observed pattern(s) (Maex et al., 2009; Sterratt et al., 2011). However, 
as the number of unknown parameters increases, typically in the context of a larger 
signalling network, it becomes exponentially more difficult to systematically search the 
parameter space and unique solutions are not guaranteed, since there may exist many 
combinations of parameters that can furnish similar outputs. An alternative approach 
to dealing with such challenges is creating simpler, reduced computational or 
mathematical models that approximate the larger network (Albert and Thakar, 2014).   
 
One approach is to reduce the complexity of the dynamic behaviour of the model that 
can be introduced when the model exhibits bi- or multi-modality is to use Boolean 
models. Such models can qualitatively recreate the temporal dynamics of a larger 
signalling network (Albert and Thakar, 2014). These models are particularly useful 
when limited kinetic details about the interaction of components are available (Albert 
and Thakar, 2014). For instance, when Boolean models are used in a gene regulatory 
network, they can describe the characteristics of circadian systems (Akman et al., 
2012; Watterson and Ghazal, 2010). These models are also employed to analyse the 
influence of stress and SSRIs in complex networks of 5-HT, neurotrophin and cortisol 
mediated signalling pathways (Moreno-Ramos et al., 2013). Notably, one such model 
predicts the network dynamics, especially when specific genes are knocked out 
(Moreno-Ramos et al., 2013).  
 
Another promising approach to minimise the number of unknown parameters in 
mechanistic models is to estimate the prior knowledge of the unknown components. 
This can be achieved by using Bayesian methods (Spiegelhalter et al., 2002). For 
example, Bayesian methods are used to deduce mechanistic parameters for amyloid 
formation kinetics (Nakatani-Webster and Nath, 2017). Other methods to reduce the 
parameter space in signalling pathways include perturbation techniques. For instance, 
Flower and Wong-Lin (2014) and Cullen and Wong-Lin (2015) used step perturbation 
technique to elucidate key model components (e.g. substrates) and their temporal 
dynamics, which lead to substantial reduction of model sizes for intracellular signalling 
in presynaptic terminals of 5-HT- and dopamine-producing neurons, respectively.  
Perhaps similar or more advanced techniques could be applied to models of 
postsynaptic 5-HT mediated signalling pathways.  
 
 
 
 
Conclusion and future directions 
 
AD is a complex neurodegenerative disorder characterised by cognitive impairment 
comorbid with behavioural changes that considerably affect day-to-day functioning. 
Neuropathologically, AD is marked by an excessive accumulation of Aβ and 
hyperphosphorylated tau protein. Currently available drugs for AD are primarily used 
to reduce symptoms or control behaviour, but not cure AD. Majority of them target 
neurotransmitter systems that include cholinergic, non-cholinergic, glutamatergic and 
their combinations.  
 
The focus of our review is to highlight the role of 5-HT system in AD. We discussed 
the 5-HTR mediated signalling pathways. These pathways are targeted by drugs such 
as SSRIs. We then discussed the role of SSRIs and 5-HTR mediated drugs in AD. 
Newer generation of antidepressant drugs such as SNRIs (e.g., venlafaxine) can 
provide an alternative route for the treatment of AD, as there is emerging evidence 
that suggests that norepinephrine system is also involved in Aβ regulation (Liu et al., 
2015; Mokhber et al., 2014; Ross et al., 2015). Hence, further modelling work on the 
interaction of neuromodulators will potentially be enlightening (Jalewa et al., 2014; 
Joshi et al., 2017a, 2015, 2011; Wang and Wong-Lin, 2013). 
 
We then highlighted the importance of the GSK-3 protein kinase, as a key kinase that 
sits in the downstream signalling pathway of most of the 5-HT receptors especially 5-
HT1AR and 5HT2AR. We then discussed existing computational models that describe 
the mechanisms that link GSK-3 to aggregation of Ab and tau hyperphosphorylation. 
Then, as an example, we suggested that both types of models could potentially be 
integrated to understand novel 5-HT based therapeutics for AD. Further, we 
highlighted the importance of reduced modelling approaches such as Boolean and 
Bayesian approaches, especially when there are many unknown parameters in a 
model or when the level of description in the data varies a lot. Abstraction of these 
models could be used as basis for models in adjacent scale, e.g. neuronal or neuronal 
network model.  
 
Taken together, we have shown that there are currently not many multiscale 
computational models of 5-HT mediated signalling pathways and their links to AD. 
Hence, there are ample opportunities for computational scientists or mathematical 
modellers in this research area. Collating and unifying models will become essential 
(Lloret-Villas et al., 2017).  
 
As hinted earlier, complementing mechanistic modelling approaches, we can also 
utilise knowledge- and data-driven approaches (Geerts et al., 2017a; Wong-Lin et al., 
(in press); Li et al., 2009). Compared to mechanistic models, non-mechanistic, data-
driven computational models can forge relationships among the input and output 
datasets, without taking into account the underpinning biological processes (Zhang et 
al., 2018). These methods largely use probabilistic or statistical methods, including 
machine learning approaches, to solve complex problems, and a key advantage is 
that they could work well with highly heterogeneous datasets (Ding et al., 2018). 
Knowledge-driven approaches make use of available literature, clinical/medical 
records, and online resources to mine relevant information (Younesi and Hofmann-
Apitius, 2013). Usually, these models operate in conjunction with data-driven models 
and can feed to other types of models (e.g., mechanistic), for example, to identify 
correlation or (probabilistic) causality for a better understanding of the relationship 
among the system’s components (e.g., proteins, enzymes) present in the intracellular 
signalling network (Younesi and Hofmann-Apitius, 2013).  
 
These types of models are highly relevant and can be used in conjunction with 
mechanistic models to understand disease mechanism(s) and potential novel 
therapeutic approaches. For instance, with such models, we could explore how drug(s) 
can activate 5-HTR mediated signalling pathways which involve GSK-3 protein kinase 
and regulates Ab and tau. Not surprisingly, interaction and parameter values of these 
pathways may be different for different brain regions. Practically, it is impossible to 
estimate the activity of these signalling pathways for all brain regions. Thus, there 
remains considerable opportunity for computational studies to estimate the activities 
of key proteins for different brain areas and link outcomes with properties that can be 
mechanistically modelled e.g. synaptic currents. These modelling features can then 
be a key ingredient to study how changes in signalling pathways can affect the function 
of neural networks via current modulation which in turn could affect cognitive 
(dys)function (Cano-Colino et al., 2013; Eckhoff et al., 2009).To achieve this, it is of 
utmost importance that experimentalists and computational modellers work together 
more synergistically.  
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